Skip to main content Back to Top
Advertisement

11/22/2022

Glucagon Injection

Products Affected - Description

    • GlucaGen lyophilized powder for injection, Boehringer Ingelheim, 1 mg, 1 mL single dose vial, 10 count, NDC 00597-0053-45 - discontinued
    • Gvoke PFS subcutaneous solution for injection, Xeris Pharmaceuticals, 0.5 mg/0.1 mL, prefilled syringe, 2 count, NDC 72065-0130-12 - discontinued
    • Gvoke PFS subcutaneous solution for injection, Xeris Pharmaceuticals, 0.5 mg/0.1 mL, prefilled syringe, NDC 72065-0130-11 - discontinued
    • Glucagon lyophilized powder for injection, Fresenius Kabi, 1 mg, 1 mL single dose vial, 10 count, NDC 63323-0596-13
    • Glucagon lyophilized powder for injection, Fresenius Kabi, 1 mg Diagnostic Kit, 1 mL vial with 1 mL vial of Sterile Water for Injection kit, NDC 63323-0593-03
    • Glucagon lyophilized powder for injection, Lilly USA, LLC, 1 mg Emergency Kit, with 1 mL of diluent in a prefilled syringe kit, NDC 00002-8031-01 - discontinued

Reason for the Shortage

    • Amphastar has glucagon 1 mg emergency kits available.
    • Boehringer Ingelheim is discontinuing GlucaGen vials and product will no longer be available after remaining inventory is depleted. The company discontinued GlucaGen diagnostic kits in September 2022.
    • Fresenius Kabi did not provide a reason for the shortage.
    • Lilly is discontinuing glucagon 1 mg emergency kits. The kits are available for ordering until December 2022. Baqsimi intranasal devices will continue to be available.
    • Novo Nordisk has GlucaGen Hypokits available.
    • Xeris Pharmaceuticals is discontinuing Gvoke prefilled syringes 0.5 mg/0.1 mL. Product will be distributed until January 30, 2023 and can be dispensed until remaining inventory is depleted. Gvoke Hypopen (2 pack) will continue to be available for pediatric patients. All other Gvoke products will continue to be available.

Available Products

    • GlucaGen Hypokit lyophilized powder for injection, Novo Nordisk, 1 mg, 1 mL vial with 1 mL syringe of Sterile Water for Injection kit, NDC 00169-7065-15
    • Gvoke Hypopen subcutaneous solution for injection, Xeris Pharmaceuticals, 0.5 mg/0.1 mL, auto-injector, 2 count, NDC 72065-0120-12
    • Gvoke Hypopen subcutaneous solution for injection, Xeris Pharmaceuticals, 1 mg/0.2 mL, auto-injector, 2 count, NDC 72065-0121-12
    • Gvoke Kit subcutaneous solution for injection, Xeris Pharmaceuticals, 1 mg/0.2 mL, vial and syringe kit, NDC 72065-0140-11
    • Gvoke PFS subcutaneous solution for injection, Xeris Pharmaceuticals, 1 mg/0.2 mL, prefilled syringe, 2 count, NDC 72065-0131-12
    • Gvoke PFS subcutaneous solution for injection, Xeris Pharmaceuticals, 1 mg/0.2 mL, prefilled syringe, NDC 72065-0131-11
    • Glucagon lyophilized powder for injection, Amphastar, 1 mg Emergency Kit,, with 1 mL of diluent in a prefilled syringe kit, NDC 00548-5850-00

Estimated Resupply Dates

    • Boehringer Ingelheim is discontinuing GlucaGen vials and product will no longer be available after remaining inventory is depleted.
    • Fresenius Kabi has glucagon 1 mg vials in 10 count and 1 mg diagnostic kits on back order and the company estimates a release date of late-December 2022.
    • Xeris Pharmaceuticals is discontinuing Gvoke prefilled syringes 0.5 mg/0.1 mL in January 2023. Product will be available until remaining inventory is depleted.
    • Lilly is discontinuing glucagon 1 mg emergency kits. The kits are available for ordering until December 2022.

Updated

Updated November 22, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created October 18, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.